Dr. Peter Rubin, MD | Biddeford, ME ...

Dr. Peter Rubin

Claim this profile

MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford

Studies Breast Cancer
Studies Lung Cancer
17 reported clinical trials
42 drugs studied

Area of expertise

1Breast Cancer
Peter Rubin has run 8 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Peter Rubin has run 7 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
MaineHealth/SMHC Cancer Care And Blood Disorders-Biddeford
Image of trial facility.
MaineHealth/SMHC Cancer Care And Blood Disorders-Sanford

Clinical Trials Peter Rubin is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Peter Rubin

Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Peter Rubin has experience with
  • Atezolizumab
  • Paclitaxel
  • Pembrolizumab
  • Gemcitabine Hydrochloride
  • Carboplatin
  • Pemetrexed Disodium

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Peter Rubin specialize in?
Is Peter Rubin currently recruiting for clinical trials?
Are there any treatments that Peter Rubin has studied deeply?
What is the best way to schedule an appointment with Peter Rubin?
What is the office address of Peter Rubin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security